Artelo Biosciences Enters $16.3 Billion Glaucoma Market with Fully Funded Clinical Trial of ART27.13
核心洞察
Artelo Biosciences (搜索) has secured a fully funded investigator-sponsored clinical trial to evaluate ART27.13, its peripherally selective synthetic cannabinoid, in glaucoma (搜索) patients with first enrollment expected in Q2 2026.
The study is funded by Glaucoma UK (搜索) and HSC R&D Division (搜索), targeting the $16.3 billion global glaucoma (搜索) market projected to grow at 7.05% annually through 2033.
ART27.13's peripheral selectivity may overcome historical limitations of cannabinoid therapies by avoiding central nervous system side effects while potentially reducing intraocular pressure through novel mechanisms.
Artelo Biosciences (搜索) has announced its entry into the ophthalmology market through a fully funded clinical study evaluating ART27.13 in glaucoma (搜索) patients. The investigator-sponsored trial represents a strategic expansion of the company's pipeline into a rapidly growing therapeutic area without requiring additional shareholder investment.
The Belfast Health and Social Care Trust will sponsor the study, with funding provided by Glaucoma UK (搜索) and the HSC R&D Division (搜索). First patient enrollment is anticipated in the second quarter of 2026, marking Artelo's first foray into ophthalmology applications for its peripherally selective synthetic cannabinoid platform.
Addressing a Growing Medical Need
Glaucoma (搜索) affects more than 80 million people worldwide and represents a leading cause of irreversible blindness. The global glaucoma market was valued at $9.46 billion in 2025 and is projected to reach $16.31 billion by 2033, growing at a compound annual growth rate of 7.05%. In the United States, 4.2 million adults had glaucoma in 2022, with projections indicating this number will reach 6.3 million by 2050.
Current treatments primarily focus on lowering intraocular pressure through topical eye drops, but these therapies often face limitations related to patient adherence, local tolerability, and long-term efficacy. Elevated intraocular pressure remains the primary modifiable risk factor for glaucoma (搜索) progression, creating an opportunity for novel therapeutic approaches.
Novel Mechanism of Action
ART27.13 is a peripherally selective synthetic cannabinoid receptor agonist designed to modulate intraocular pressure through activation of cannabinoid receptors (搜索) in peripheral tissues, including ocular tissues. Preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow—two key mechanisms involved in intraocular pressure regulation.
The compound's peripheral selectivity represents a potential breakthrough in cannabinoid-based glaucoma (搜索) treatment. While the therapeutic potential of cannabinoids in managing intraocular pressure has been recognized since the 1970s, their clinical application has been limited by central nervous system effects.
"The potential role of peripherally selective cannabinoids in ocular health is an exciting and largely unexplored area," said Professor Augusto Azuara-Blanco, Clinical Professor of Ophthalmology at Queen's University Belfast and the study's principal investigator. "This study will provide important insights into whether ART27.13, which is designed to act outside the central nervous system, can safely lower intraocular pressure without psychotropic side effects."
Study Design and Leadership
The pilot study, titled "A Pilot, Randomized, Cross-Over Study to Determine the Effects of an Oral, Peripherally Selective, Synthetic Cannabinoid ART27.13 on Intraocular Pressure," will be conducted by the Northern Ireland Clinical Trials Unit (搜索). The cross-over design allows each patient to serve as their own control, potentially increasing statistical power while reducing required enrollment numbers.
Professor Azuara-Blanco, a globally recognized authority in glaucoma (搜索) management and clinical research, will lead the investigation. The study protocol has received approval from the ethics committee and the Medicines and Healthcare products Regulatory Agency (MHRA).
Under the agreement, Artelo will supply ART27.13 capsules as the investigational medicinal product for oral administration in the study.
Strategic Pipeline Expansion
The glaucoma (搜索) study represents a capital-efficient approach to expanding ART27.13's therapeutic profile beyond its lead indication in cancer-related anorexia (搜索). The investigator-sponsored trial structure shifts the financial burden while allowing Artelo to maintain strategic control and retain data rights.
"This investigator-initiated study represents an important collaboration and a potential expansion of ART27.13's therapeutic profile beyond cancer-related anorexia (搜索)," said Greg D. Gorgas, President and Chief Executive Officer of Artelo Biosciences (搜索). "We believe this collaboration also exemplifies our capital-efficient development strategy—leveraging high-quality investigator-initiated research to broaden the potential utility of our compounds while preserving our internal focus on ART27.13's lead indication."
ART27.13 has been evaluated in seven clinical studies involving over 280 participants. The compound demonstrated a statistically significant and dose-dependent increase in body weight in people with back pain who were otherwise healthy. In the Phase 2 portion of the CAReS trial, positive interim data showed improvements in body weight, lean body mass, and physical activity alongside a favorable side-effect profile in cancer-related anorexia (搜索) patients.
Intellectual Property Protection
Artelo recently received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13, extending patent protection through December 2041. This intellectual property milestone strengthens the commercial potential of the compound across multiple therapeutic applications.
The company's diversified pipeline targets lipid-signaling pathways addressing unmet medical needs across oncology, pain, dermatology, and neurological conditions, with ART27.13 serving as a cornerstone asset with broad therapeutic potential.